CTOs on the Move

Illumina

www.illumina.com

 
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet ...
  • Number of Employees: 5K-10K
  • Annual Revenue: $500M-1 Billion
  • www.illumina.com
  • 5200 Illumina Way
    San Diego, CA USA 92122
  • Phone: 858.202.4500

Executives

Name Title Contact Details
Steven Barnard
Vice President and Chief Technology Officer Profile
Carissa Rollins
Chief Information Officer Profile
Jason Banthrum
Assoc Director, Application Security and Compliance Profile
Alex Aravanis
Chief Technology Officer and Head of Research and Product Development Profile
Alex Aravanis
Chief Technology Officer Profile

Similar Companies

Aspen Medical Products

Aspen Medical Products is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Home Advantage

Home Advantage is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vibrac Animal Health

Vibrac Animal Health is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genizon BioSciences

Genizon BioSciences Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia.